Crebinostat is a histone deacetylase inhibitor and epigenetic modulator primarily investigated for its potential in treating solid tumors, including non-small cell lung cancer and pancreatic ductal adenocarcinoma.… Read more
Crebinostat is a histone deacetylase inhibitor and epigenetic modulator primarily investigated for its potential in treating solid tumors, including non-small cell lung cancer and pancreatic ductal adenocarcinoma. By inhibiting specific HDAC enzymes, this compound works to increase the expression of tumor suppressor genes and induce apoptosis within malignant cells. Researchers and pharmaceutical scientists utilize the accompanying reference standards, metabolic metabolites, and stable isotope-labelled compounds in this category to facilitate rigorous analytical testing. These high-quality materials are critical for accurate impurity profiling, method validation, and ongoing quality control of pharmaceutical formulations throughout the drug development lifecycle. By incorporating these precise chemical tools, laboratories can ensure the integrity of their results while supporting the advancement of oncology research and the characterization of complex therapeutic agents like Crebinostat.